Cubosome nanoparticles potentiate immune properties of immunostimulants

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 3571-3583

  Liu, Zhenguang ^a   Luo, Li ^a   Zheng, Sisi ^a   Niu, Yale ^a   Bo, Ruonan ^a   Huang, Yee ^a   Xing, Jie ^a   Li, Zhihua ^a   Wang, Deyun ^a  

^a NANJING AGRICULTURAL UNIVERSITY   (China)

Author keywords

Cryo FESEM; Cubosomes; Dendritic cells; Lymph nodes; Memory T helper cells; Polysaccharides

Indexed keywords

CUBOSOME; DRUG CARRIER; NANOPARTICLE; POLYSACCHARIDE; UNCLASSIFIED DRUG; ANTIGEN; CYTOKINE; IMMUNOLOGICAL ADJUVANT; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; FEMALE; FIELD EMISSION SCANNING ELECTRON MICROSCOPY; HELPER CELL; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPH NODE; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; X RAY CRYSTALLOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CRYOELECTRON MICROSCOPY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PERITONEUM MACROPHAGE; SCANNING ELECTRON MICROSCOPY; SMALL ANGLE SCATTERING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; CRYOELECTRON MICROSCOPY; CYTOKINES; DENDRITIC CELLS; FEMALE; LYMPH NODES; MACROPHAGES, PERITONEAL; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; POLYSACCHARIDES; SCATTERING, SMALL ANGLE; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES;

EID: 84982712520     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S110406     Document Type: Article

References (33)

1. Pavot V, Rochereau N, Primard C, et al. Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties. J Control Release. 2013;167(1):60–67.
2. Wang W, Singh M. Selection of adjuvants for enhanced vaccine potency. World J Vaccines. 2011;1(2):33.
3. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503.
4. De Haan A, Tomee J, Huchshorn J, Wilschut J. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. Vaccine. 1995;13(14):1320–1324.
5. Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011;470(7335):543–547.
6. Fong W-K, Hanley T, Boyd BJ. Stimuli responsive liquid crystals provide ‘on-demand’drug delivery in vitro and in vivo. J Control Release. 2009;135(3):218–226.
7. Lopes LB, Lopes JL, Oliveira DC, et al. Liquid crystalline phases of monoolein and water for topical delivery of cyclosporin A: characterization and study of in vitro and in vivo delivery. Eur J Pharm Biopharm. 2006;63(2):146–155.
8. Angelova A, Angelov B, Lesieur S, et al. Dynamic control of nanofluidic channels in protein drug delivery vehicles. J Drug Deliv Sci Technol. 2008;18(1):41–45.
9. Leser ME, Sagalowicz L, Michel M, Watzke HJ. Self-assembly of polar food lipids. Adv Colloid Interface Sci. 2006;123–126:125–136.
10. Shen HH, Lake V, Le Brun AP, et al. Targeted detection of phosphatidylserine in biomimetic membranes and in vitro cell systems using annexin V-containing cubosomes. Biomaterials. 2013;34(33):8361–8369.
11. Rizwan SB, McBurney WT, Young K, et al. Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses. J Control Release. 2013;165(1):16–21.
12. Pi CC, Chu CL, Lu CY, et al. Polysaccharides from Ganoderma formosanum function as a Th1 adjuvant and stimulate cytotoxic T cell response in vivo. Vaccine. 2014;32(3):401–408.
13. Liu Z, Ma X, Deng B, et al. Development of liposomal Ganoderma lucidum polysaccharide: formulation optimization and evaluation of its immunological activity. Carbohydr Polym. 2015;117:510–517.
14. Kazzaz J, Singh M, Ugozzoli M, Chesko J, Soenawan E, O’Hagan DT. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J Control Release. 2006;110(3):566–573.
15. Singh M, Chakrapani A, O’Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines. 2007;6(5):797–808.
16. Ye Y, Huang X, Zhang Y, et al. Calcium influx blocked by SK&F 96365 modulates the LPS plus IFN-γ-induced inflammatory response in murine peritoneal macrophages. Int Immunopharmacol. 2012;12(2):384–393.
17. Rizwan SB, Dong YD, Boyd BJ, Rades T, Hook S. Characterisation of bicontinuous cubic liquid crystalline systems of phytantriol and water using cryo field emission scanning electron microscopy (cryo FESEM). Micron. 2007;38(5):478–485.
18. Hinton TM, Grusche F, Acharya D, et al. Bicontinuous cubic phase nanoparticle lipid chemistry affects toxicity in cultured cells. Toxicol Res. 2014;3(1):11–22.
19. Kojarunchitt T, Baldursdottir S, Dong YD, Boyd BJ, Rades T, Hook S. Modified thermoresponsive poloxamer 407 and chitosan sol-gels as potential sustained-release vaccine delivery systems. Eur J Pharm Biopharm. 2015;89:74–81.
20. Lefeber DJ, Benaissa-Trouw B, Vliegenthart JF, et al. Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infect Immun. 2003;71(12):6915–6920.
21. McHeyzer-Williams M, Okitsu S, Wang N, McHeyzer-Williams L. Molecular programming of B cell memory. Nat Rev Immunol. 2012;12(1):24–34.
22. Henriksen-Lacey M, Christensen D, Bramwell VW, et al. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N′, N′-dimethylaminoethane) carbomyl] cholesterol (DC-Chol), and 1, 2-dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. Mol Pharm. 2010;8(1):153–161.
23. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745–763.
24. Liu H, Wang Y, Wang Q, et al. Protein-bearing cubosomes prepared by liquid precursor dilution: inner ear delivery and pharmacokinetic study following intratympanic administration. J Biomed Nanotechnol. 2013;9(10):1784–1793.
25. Yaghmur A, Glatter O. Characterization and potential applications of nanostructured aqueous dispersions. Adv Colloid Interface Sci. 2009;147–148:333–342.
26. Boyd BJ, Rizwan SB, Dong YD, Hook S, Rades T. Self-assembled geometric liquid-crystalline nanoparticles imaged in three dimensions: hexosomes are not necessarily flat hexagonal prisms. Langmuir. 2007;23(25):12461–12464.
27. Sagalowicz L, Michel M, Adrian M, et al. Crystallography of dispersed liquid crystalline phases studied by cryo-transmission electron microscopy. J Microsc. 2006;221(pt 2):110–121.
28. Gao W, Fang RH, Thamphiwatana S, et al. Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano Lett. 2015;15(2):1403–1409.
29. Xu L, Liu Y, Chen Z, et al. Morphologically virus-like fullerenol nanoparticles act as the dual-functional nanoadjuvant for HIV-1 vaccine. Adv Mater. 2013;25(41):5928–5936.
30. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res. 2012;72(14):3439–3444.
31. del Pozo Balado Mdel M, Leal M, Méndez Lagares G, et al. Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. J Infect Dis. 2010;202(3):362–369.
32. Robinson HL, Amara RR. T cell vaccines for microbial infections. Nat Med. 2005;11(4):S25–S32.
33. Xu L, Liu Y, Chen Z, et al. Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment. Nano Lett. 2012;12(4):2003–2012.